This page contains a Flash digital edition of a book.
Mind & Brain, the Journal of Psychiatry


considerable time, effort, and resources during the process in which we planned our Node and submitted an application to NIDA. Although not all of our CTPs have participated in a CTN clinical trial, all have contributed to the research agenda of our Node and the CTN, participated in CTN and Node committees, and contributed to dissemination activities of the CTN, our Node, and in their local communities. As a result of participation in the CTN and intra-Node collaboration, all CTPs report a significant increase in their use of EBPs such as motivational incentives, motivational interviewing, twelve- step facilitation therapy, treatment planning, buprenorphine treatment, nicotine addiction, and co-occurring disorders treatment.


The ATS has participated, or is currently participating, in six


multi-site studies conducted by the CTN since 2005. In addition to participating as research sites in these studies, our Node also served on protocol development and/or the study executive committees on five of these studies, thus contribut- ing significantly to the scientific agenda of the CTN.


The CTN From the Perspective of Community Treatment Providers (CTPs)


Following are comments from several of our CTPs and clinicians regarding their experiences in the CTN thus far. These evidence their commitment to the CTN and the benefits to clinical staff and patients served in their clinical programs.


Meridian (Ohio) While we have not had the opportunity to participate in any


of the clinical trials to date, we have derived significant benefit from our participation in the CTN. Our biggest benefit is receiving top notch training events that the ATS Node has made available for our staff that focused specifically on promoting evidence-based practices. Although Ohio has been focusing on promoting EBPs for some time, the twelve- step facilitation training helped us train our clinicians on becoming more effective in facilitating the integration of new clients in actively engaging in mutual support programs like AA or NA. Our agency also makes personal contacts with people willing to serve as ‘‘temporary sponsor’’ to our clients. One clinician stated ‘‘the TSF training gaveme direction that I brought back to the agency and inspired my perspective on implementing a new curriculum in TSF groups. It also gave me a push to focus more on helping clients ‘get active’ rather than approach participation in mutual support programs in a passive manner. I learned a new way of looking at TSF treatment interventions and goals with clients.’’


Another significant benefit was the on-site and telephone


contact we had with our CTP colleagues in West Virginia to learn about their use of Suboxone for opioid-dependent patients. Collaborating with these colleagues helped us to identify the aspects that were most important for the program we wanted to create. It also helped to alleviate and normalize some of our concerns in providing this medication along with a behavioral treatment program. To date, we are having very good success with our Suboxone program.


M&B 2011; 2:(1). July 2011 58


The RRTC has served as an excellent resource for our clinical staff, providing us with EBP training materials, client and family recovery materials, and answering questions such as what diagnostic screening tool for adolescents would be the best for our agency to use.


Chestnut Ridge Center (CRC, Morgantown, West Virginia)


Participating in the CTN has been a journey. The CRC became involved in this network that spoke of Nodes, had copious numbers of acronyms, and promised the involvement in cutting edge research. Since the beginning, the benefits of our involvement at the CRC have been abundant with one benefit leading to another. The CRC has been involved in two large-scale multi-site studies, which has led to more highly trained clinicians as well as an increase in knowledge about effective treatments and the use of EBPs. This, in turn, has led to better clinical services for our patients and community. The CTN has promoted involvement and training in the dissemi- nation process of new treatments. This part of our CTN involvement has changed the treatment horizon not just for our patient population and local community but for the tri- state area since our faculty and staff provide extensive training programs on EBPs for other providers.


One example of a change implemented at CRC as a result of


our CTN involvement is seen in our services to the opioid dependent population. In the late 1990s, there was a surge in opioid dependence in our rural environment. Treatment within the context of our ongoing addiction treatment programs was an option for these patients, but new EBPs offered fresh alternatives. Suboxone combined with psycho- social treatment was a novel choice. Because of the influence of the CTN, we have developed a clinic model of treatment of opioid dependence that treats about 300 patients at any given time with a combination of evidence-based medication assisted and psychosocial treatments (group drug counseling and twelve-step facilitation therapy) in a graduated model. Involvement in the CTN has meant we have a team of trained treatment providers who are excited about new effective treatments. It has directly influenced our care, through providing new treatments, upgrading provider skills and knowledge, and changing the outcomes for our patients.


The real jewel in the CTN is the participation in multi-site


studies. Our patients are proud and feel privileged to be a part of these studies. Our providers are influenced to be adherent with specific methods and hold deeper respect for scientific outcomes. While the community treatment programs bring the ‘‘real patient’’ to the studies, participating in the studies changes the providers as well. It trains providers to think more scientifically about the treatment they are delivering. For example, in our experience with one of the buprenor- phine studies, staff became well-trained on the understanding of the use and the limitations in use of buprenorphine. They experienced first-hand the value of combining EBPs in patient care. Since the end of this study, our staff has been active in dissemination efforts. Most recently, a series of six 8-hour trainings on treatment for opioid addiction were delivered across the state to physicians and other clinicians caring for


www.slm-psychiatry.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89